Table 1.
Patient and transplant characteristics.
| Variable | Non-acute graft-versus-host disease (aGVHD) (n = 49) | II–IV aGVHD (n = 32) | p |
|---|---|---|---|
| Age, median years (range) <33 (%) |
33 (16–54) 22 (44.9) |
33 (17–55) 15 (46.9) |
0.869 0.861 |
| Gender (%) | |||
| Female | 19 (38.8) | 11 (34.4) | 0.688 |
| Donor gender (%) | |||
| Female | 13 (26.5) | 7 (21.9) | 0.635 |
| Pretransplant comorbidity [Hematopoietic-cell transplantation comorbidity index (HCT-CI)] | |||
| 0–1 2–3 |
41 (83.4) 8 (16.3) |
23 (71.9) 9 (28.1) |
0.202 |
| Underlying disease (%) | |||
| AML ALL MDS |
29 (59.2) 17 (34.7) 3 (6.1) |
20 (62.5) 10 (31.3) 2 (6.2) |
0.949 |
| Disease risk | |||
| High (%) Low or intermediate |
26 (53.1) 23 (46.9) |
19 (59.4) 13 (40.6) |
0.576 |
| Disease status | |||
| CR Non-CR |
39 (79.6) 10 (20.4) |
25 (78.1) 7 (21.9) |
0.874 |
| Conditioning (%) | |||
| Intensified Standard |
10 (20.4) 39 (79.6) |
13 (40.6) 19 (59.4) |
0.049 |
| TBI Non-TBI |
17 (34.7) 32 (65.3) |
8 (25.0) 24 (75.0) |
0.356 |
| Donor type (%) | |||
| MSD HID |
26 (53.1) 23 (46.9) |
15 (46.9) 17 (53.1) |
0.653 |
| Graft source, No. (%) | |||
| BM + PBSC PBSC |
19 (38.8) 30 (61.2) |
11 (34.4) 21 (65.6) |
0.688 |
| Cell yield MNC (median) (108/kg) | 8.1(4.3–14.6) | 8.2 (5.4–14.3) | 0.587 |
| Antibiotics (%)a | |||
| b-lactamb Vancomycin (intravenous) Amikacin |
36 (73.5) 25 (51.0) 24 (49.0) |
31 (96.9) 20 (62.5) 19 (59.4) |
0.006 0.309 0.359 |
| Bloodstream infection | 8 (16.3) | 8 (25.0) | 0.338 |
aEvaluated between conditioning and engraftment time.
bb-lactams include carbapenem, cephalosporin, and b-lactam-b-lactamase combinations.
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BM, bone marrow; HID, haploidentical donor; MDS, myelodysplastic syndrome; MNC, mononuclear cell; MSD, matched sibling donor; PBSC, peripheral blood stem cell; TBI, total body irradiation.